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Abstract 
Dysregulated expression of ephrin type-B receptor 2 (EphB2) has been linked with development and 
progression of solid tumours. In the current study we attempted to investigate the clinical relevance in 
GC and the effect of EphB2 expression on gastric cancer (GC) cells. EphB2 protein levels in GC and 
benign gastric tissues were determined using immunohistochemistry. EphB2 transcript expression in a 
GC cohort with GC tissue samples (n=171) and paired adjacent normal gastric tissues (n=97) was 
determined using qPCR. The EphB2 expression was over-activated using a CRISPR activator for the 
investigation of its cellular function. The expression levels of the EphB2 protein in the tumour tissues 
of tissue arrays were higher than the benign non-cancerous gastric tissues (P<0.05). EphB2 mRNA 
expression in GC tissues was also significantly elevated when compared with adjacent non-cancerous 
tissues (P<0.01). EphB2 activation promoted the migration and invasion abilities of the GC cell lines 
(P<0.01, respectively). In contrast, EphB2 activation significantly decreased the adhesion in GC cells 
(P<0.0001, respectively). The enrichment analysis of the correlated genes in a GC cohort indicates that 
EphB2 may function through mediating the cytokine-cytokine interaction, JAK-STAT and TP53 
signaling pathways. In conclusion, EphB2 represents as a novel independent prognostic marker in GC. 
And activation of the EphB2 gene expression elevated the levels of migration and invasion, but 
suppressed adhesion of GC cells, indicating that EphB2 may act as a tumour promotor in GC.  Our 
findings thus provide fundamental evidence for the consideration of the therapeutic potential of 
targeting EphB2 in GC. 
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Introduction 
 
The human ephrin receptors (Ephs) consist of 16 members and are categorised into two groups: 
Eph A (EphA1-8, 10) and EphB (EphB1-4, 6). The Eph receptors and their membrane-
anchored ephrin ligands regulate tumourigenesis and tumour-associated angiogenesis [1, 2]. 
The formation of an ephrin–Eph heterotetramer complex can trigger multiple downstream 
pathways, such as the Ras (R-Ras, H-Ras, N-Ras) and Rho (Rho, Rac1, Cdc42) family of small 
GTPases. Ephs play diverse and essential roles in cancer cells including modulating migration, 
proliferation, cytoskeletal dynamics, adhesion and invasion [3]. Aberrant expression or 
mutations of Eph receptors are associated with tumour promotion or progression in lung, breast 
and colon cancer [4-6]. 
Among the five human EphB receptors, EphB2 has been extensively studied in several types 
of solid tumours. In glioma tumour, EphB2 regulates cell migration, growth and adhesion 
probably through the activation of the R-Ras pathway [7, 8]. A higher level of EphB2 protein 
expression is associated with better clinical outcomes including both overall and recurrence-
free survival of patients with colorectal cancer. However other studies suggest that EphB2 may 
be an invasion-driver gene in colorectal cancer [9, 10]. Loss-of-function mutation of EPHB2 
may also be involved in the progression and metastasis of prostate cancer [11].  
Gastric cancer (GC) is the fourth most common cancer in men and the seventh most common 
cancer in women worldwide. Approximately 1 million new cases are diagnosed annually [12].  
GC is also the second most common cause of cancer-related deaths in the world. GC is often 
diagnosed at an advanced stage, and its prognosis is often poor with a median OS of less than 
1 year. Therefore there is an unmet need for an enhanced understanding of the biology of this 
disease before developing more efficient therapies. The clinical significance EphB2 in GC 
remains controversial so far.  It is reported that EphB2 is elevated in early-stage GC, but the 
loss of EphB2 expression tends to correlate with poor survival of the patients with GC [13, 14].  
A previous study using tissue array also indicates that there may be a high level of EphB2 
protein expression in intestinal adenocarcinoma of the stomach although there is no gene 
expression data presented to support it [15]. There is also a report suggesting that high EPHB2 
mutation rate maybe associated with microsatellite instability in GC compared with 
endometrial tumours using limited sample size [16]. Therefore in this study, we aimed to 
evaluate the prognostic value and determine the functions of EphB2 in GC.  A gastric tissue 
microarray was used to investigate the association of the EphB2 protein expression with gastric 
cancer by immunohistochemistry. We examined the gene expression of EphB2 in a GC cohort. 
The functional role of EphB2 was determined using gastric cancer cells following CRISPR-
mediated EphB2 gene expression activation. The regulation pathways that EphB2 is involved 
were explored by bioinformatic analysis after pooling the significantly correlated genes with 
EphB2 in our GC cohort.   
 
Materials and methods 
Cell lines and culture conditions 
Human GC cell lines AGS and HGC27 were purchased from the European Collection of Cell 
Cultures (ECACC; Salisbury, UK) and incubated at 37˚C, with 5% CO2 and 95% humidity. 
These cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal calf serum (PAA Laboratories Ltd., Somerset, UK), and 1% 
penicillin, streptomycin and amphotericin B (Sigma-Aldrich, Dorset, UK). 
Tissue array Immunohistochemistry (IHC) 
The gastric carcinoma tissue microarray (130 cases/390 cores) contained 83 cases of gastric 
carcinoma, 27 cases of esophagogastric junction carcinoma and 20 cases of benign tissue 
samples including adjacent tissue (10cases) and chronic gastritis tissue (10cases) (OD-CT-
DgStm01-007, US Biomax, Inc, Rockville, MD, USA). The clinicopathological characteristics 
including pathological stage, grade, and nodal status were provided on the supplier’s website. 
Standard indirect biotin-avidin immunohistochemical analysis was used to evaluate the EphB2 
protein expression. Briefly, prior to staining, slides were placed in an oven set no higher than 
55˚C for 1 day to help the sections adhere to the slide. The tissue array section was then 
dewaxed with xylene and ethanol, and gradually hydrated. Antigen retrieval was performed by 
placing slides in a plastic container and covered with antigen retrieval buffer, in the microwave 
on full power for 20 minutes. The rabbit anti-EphB2 antiserum with working concentration 
(1mg/ml) was incubated at 4˚C overnight. The slides were then washed with Tris Buffered 
Saline (TBS), and incubated with a universal biotinylated secondary antibody (ABC Elite Kit, 
Vectastain Universal, PK-6200, Vector Laboratories, CA, USA) for 30 minutes. Following 
washing with TBS, the sections were incubated with avidin-biotin-peroxidase complex (ABC) 
for 30 minutes. The 3, 3'-diamino-benzidine (DAB) substrate (5 mg/ml) was used to develop 
the final reaction product. The sections were then rinsed in water, counterstained with Gill's 
hematoxylin (Vector Laboratories) and dehydrated through a series of graded alcohols, cleared 
in xylene and mounted in DPX/Histomount (Merck Millipore, UK).  Images were captured 
using an EVOS FL Auto 2 Cell Imaging System (ThermoFisher Scientific).  
All IHC images were manually read by two pathologists who were blinded to the clinical 
information. The semi-quantitative scoring method was employed to evaluate the intensity of 
EphB2 positive expression scores (0: negative; 1: weak; 2: moderate; 3: strong). The 
percentage of the staining was scored. The two scores were added (0: none, 1:  1% to 33%; 2:  
34% to 66%; 3: 67% to 100%).  The total scores of 0–2 were considered as negative and 3–6 
as positive. 
Patients and clinical data 
Gastric adenocarcinoma and Siewert type III gastro-oesophageal junction adenocarcinoma 
tissues (n=171) with matched adjacent background tissues (n=97) were collected immediately 
after surgical resection at the Beijing Cancer Hospital with informed consent from the patients. 
The patient selection criteria in this study were defined as follows: 1. Aged from 18 years old; 
2. Histologically proven gastric cancer; 3. Subjected to surgical resection without any prior 
treatment. The tissue samples were stored at -80˚C at the Tissue Bank in Peking University 
School of Oncology with a record of the relevant clinical and histopathological data. All 
protocols were reviewed and approved by the Beijing Cancer Hospital Research Ethics 
Committee (MTA10062009). The clinicopathological data of our GC cohort were shown in 
Table 1.  
RNA isolation and quantitative real-time PCR (qPCR) 
Total RNA was extracted from fresh frozen gastric tissues and cultured GC cell lines using TRI 
reagent (Sigma-Aldrich, Dorset, UK) following the manufacturer’s instruction. First strand 
cDNA was synthesized from 1 μg RNA using a first-strand DNA synthesis kit (Bio-Rad, Hemel 
Hempstead, UK). Quantitative analysis of EphB2 mRNA expression in GC tissues was 
performed using Amplifluor™‑based real-time PCR, in which a 6-carboxy-fluorescine-
taggedUniprimer™ (Biosearch Technologies, Inc.) was used as a probe along with a pair of 
specific primers with an addition of a Z-sequence (actgaacctgaccgtaca) to the 5'-end of the 
reverse primer. The quality of cDNA samples was verified using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as a housekeeping gene. The primer sequences for qPCR were as 
follows:  
EphB2-forward: TTGAGAATGGCACCGTCT; 
EphB2-reverse: ACTGAACCTGACCGTACAGATGGGACAGTGGGTACAG;  
GAPDH-forward: AAGGTCATCCATGACAACTT; 
GAPDH-reverse: ACTGAACCTGACCGTACAAGCCATCCACAGTCTTCTG.  
Kaplan–Meier survival analysis 
We performed the survival analysis using the gene expression data obtained from our cohort. 
As a comparison,  the association between EphB2 gene expression and survival of patients with 
GC was assessed using an online Kaplan–Meier survival analysis tool (http://kmplot.com) [17]. 
This online tool allowed us to analyze the OS from 876 cases, FP from 641 cases and PPS from 
499 cases of GC by pooling all the published Affymetrix gene expression microarray data 
(EphB2 Probe set ID: 211165_x_at, 209588_at, 210651_s_at and 211165_x_at).  
Transfection with EphB2 plasmid 
The CRISPR activation plasmid specific for EphB2 was obtained from Santa Cruz 
Biotechnology, INC. AGS and HGC27 cells were transfected with 1 µg of the CRISPR 
activation plasmid specific for EphB2 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) 
in Opti-MEM Medium using Lipofectamine™ 3000 Transfection Reagent (ThermoFisher, 
USA) according to the manufacturer’s instruction.  
Western blot analysis 
Protein samples following cell lysis were separated using SDS-PAGE followed by 
electroblotting onto a nitrocellulose membrane (Millipore Ltd, Watford, UK). The proteins 
were then probed with the anti-EphB2 antibody (1:1,000, Signalway Antibody SAB, Pearland, 
USA) and anti-GAPDH antibody (1:5,000, Santa Cruz Biotechnology, Inc.) as a house keeping 
control, followed by a peroxidase-conjugated secondary antibody (1:2,000, Sigma). Protein 
bands were visualized using a chemiluminescence detection kit (Luminata, Millipore) and 
photographed with the gel documentation system G: Box (Syngene Europe, Cambridge, UK).  
Flow cytometric analysis 
Cells were harvested and washed in ice cold PBS and resuspended in 1X Annexin-binding 
buffer at a density of 1x106 cells/ml after centrifugation. FITC Annexin V (5 µl) and PI working 
solution (1 µl) (100 µg/ml) (Molecular Probes, Eugene, OR, USA) were added to 100 µl of the 
cell suspension. After incubation for 30 minutes at room temperature, 400 µl of 1X 
Annexin-binding buffer was added, mixed gently and the samples were kept on ice. The stained 
cells were immediately analyzed by flow cytometry (FACS CantoTM II, BD BioSciences, San 
Jose, CA, USA).  
In-vitro cell proliferation assay 
Cells were seeded into 96-well plates in complete growth culture medium at a density of 5000 
cells/well. Following cultivation for 24 and 48 hours, respectively, cells were fixed with 4% 
formaldehyde followed by staining with 0.5% crystal violet. The crystal violet was then 
dissolved in 10% acetic acid prior to a colorimetric detection at a wave length of 580 nm using 
the ELx800 spectrophotometer.  
In-vitro invasion assay 
The 24-well transwell plate inserts with 8-μm pores (Greiner Bio-one, Frickenhausen, 
Germany) were pre-coated with 30 μg/well of Matrigel (BD Bioscience, Oxford, UK) and air-
dried. Cells at a density of 30,000 cells/well were seeded to each well after 60-min rehydration 
of the Matrigel using PBS. After incubation for 24 h, cells that invaded through the Matrigel 
matrix to the other side of the insert were detached with an enzyme-free cell dissociation 
solution and stained with the DNA-binding fluorescent stain Hoechst 33342 (Sigma). The cell 
number was then determined by measuring fluorescence signal (excitation, 340-380 nm; 
emission, >415 nm) using a 96-well plate reader (GloMax, Promega, oxford, UK).  
Cell-matrix adhesion assay  
The 96-well culture plates were pre-coated with 5 μg/well of Matrigel and air‑dried. Following 
the rehydration, 20,000 cells were seeded into each well. After incubation for 40 min, non-
adherent cells were washed-off using PBS. The number of adherent cells was counted after 
fixation and staining using crystal violet as described above. 
Electric cell-substrate impedance sensing (ECIS) analysis 
The Electric Cell–Substrate Impedance Sensing (ECIS™) 9600 system (Applied Biophysics, 
Troy, NJ) was used to analyze the attachment and migratory behaviour of GC cells. Briefly, 
AGS and HGC27 cells were seeded onto ECIS 96W1E arrays and the migration of cells to the 
culture surface between the two electrodes was monitored by measuring electrical resistance. 
Once a confluent monolayer had been formed, the cells were damaged by applying an electric 
current (2600 µA, 60 kHz) for 20 seconds to create a break in the cell monolayer. The rate of 
change in impedance as cells migrated back onto the electrode sensing site was subsequently 
monitored and analyzed. 
Wound healing assay 
Cells were cultivated until they reached confluency. A scrape in the cell monolayer was made 
in one direction with a fine pipette tip. The wounded cell monolayers were washed with PBS 
to remove cell debris. The remaining gaps which indicated the wound-healing migration ability 
of the cells were analyzed using an inverted microscope at different time points.  
Bioinformatic analysis 
The gene expression correlation in our GC cohort was analyzed using the Pearson correlation 
test. The enrichment analysis of the significantly correlated genes was performed using the 
Cytoscape program [18] and the ConsensusPathDB plugin [19, 20]. The protein associated 
interaction network was predicted using the STRING program [21].  To confirm the 
observation from our patient cohort, we also performed pooled bioinformatic analysis of 
mRNA expression using the publicly available Cancer Genome Atlas Stomach 
Adenocarcinoma (TCGA-STAD) data base with 415 GC tumour samples and 35 normal gastric 
tissue controls.   
Statistical analysis 
All statistics were conducted with the  R language (Version 3.6.1) [22]   using RStudio (Version 
1.2.1335. R Studio Inc., Boston, Massachusetts, USA). Kruskal-Wallis or Wilcoxon test was 
used for the comparison of non-parametric data, while ANOVA or t-test was used if data pass 
the Shapiro normality test. Results were considered to be statistically significant when p<0.05. 
 
RESULTS 
Protein levels of EphB2 are higher in human GC tissue 
We assessed the association of the EphB2 staining scores following IHC with the 
clinicopathological variables of the tissue microarray including tissue type, Pathological 
diagnosis, pTNM stage and histological grade. As shown in Fig.1, The staining scores of 
EphB2 were significantly higher in malignant tumour tissues than benign ones (P= 0.018). Also, 
the protein levels of EphB2 in late stages (II, III and IV) tended to be upregulated (P= 0.0072). 
There was no significant association of the EpHB2 IHC staining levels with the grade (P= 0.08), 
sex (P= 0.073) and pathological types (P= 0.36) of GC.  
Higher expression of EphB2 in transcript levels of human GC 
Transcript levels of EphB2 were determined in our GC cohort using real-time qPCR. The 
results showed that EphB2 expression was significantly upregulated in gastric tumours 
compared to normal tissue (P=0.0020) (Table II). The differentiated expression level EphB2 in 
GC was also observed between genders, male GC patients exhibited higher expression than 
female (P=0.0056). The transcript level of EphB2 in the stages III+IV stages was significantly 
higher than the stages of I+II (p=0.0480), which appeared to be in line with the observation of 
the protein expression by IHC. There was also a higher gene expression of EphB2 in tissues 
from patients who received radical surgical treatment than those who received Non-Radical 
surgery. The higher mRNA expression of EPHB2 in gastric tumours was also confirmed by 
the data analysis of the TCGA-STAD database as shownd in Supplement Figure 3(p<0.0001).   
Association of EphB2 expression with the survival of patients with GC 
We performed the Kaplan–Meier survival analysis using the gene profile data from our cohort. 
It showed that high transcript expression of EphB2 appeared to be linked with poor overall 
survival (OS) although the statistical significance was not reached according to the log Rank 
test (P=0.145) despite the P value by Breslow test is 0.049 (Figure 2A). As a comparison, we 
also evaluated survival using the online KMplot database (Figure 2B-2E). Within the four 
probe set IDs of EphB2, two of them indicated that high gene expression of EphB2 is associated 
with poor OS  including 210651_s_at (P=0.0082) and    211165_x_at (P=0.039),    one of them 
indicated opposite association (209588_at, P=0.034), while one of them did not show any 
significance (209589_s_at, P=0.23). 
CRISPR-mediated activation of EphB2 in GC cells 
As the endogenous expression levels of EphB2 in HGC27 and AGS wild type cells were 
relatively low after initial evaluation (Supplement Figure 2), we attempted to activate the 
EphB2 expression using the CRISPR-mediated EphB2 activator. The change of the EphB2 
expression was examined using qPCR, Flow cytometry and Western blotting in comparison 
with the WT control. The Flow cytometric data indicated that there was a dramatic increase in 
EphB2 expression in cells after treatment with the EphB2 activator in both AGS and HGC27 
cells (Figure  3A). The Western blotting confirmed the result of flow cytometry (Figure  3B 
and 3C). The qPCR data showed that there was a higher expression of EphB2 gene in the 
EphB2 activation group compared with the controls (4- to 7-fold) (Figure  3D).  
Activation of EphB2 enhances the migration ability of the GC cells 
As indicated by the ECIS system (Figure  4A and 4B), the migration levels of both gastric cells 
were enhanced significantly in cells with EphB2 activation compared to the vehicle and WT 
controls (p<0.01, respectively). The scratch wound-healing assay was performed to evaluate 
migration in a directly visible but low-accuracy manner. As shown in Figure  4C and 4D, 
EphB2 activation for 12 hours accelerated the closure of the gap area indicating the elevated 
migration ability of AGS (P=0.0031 vs WT). However, there was no difference in terms of the 
wound healing closure speed in HGC27 cells (P=0.59) (Figure  4E and 4F). 
Activation of EphB2 reduces the adhesion ability of the GC cells. The effect of EphB2 
activation on the adhesive ability of GC cell lines was evaluated using an in vitro matrix 
adhesion assay. As shown in Figure  5A and 5B, EphB2 activation reduced the adhesion ability 
of both AGS and HGC27 cells significantly (p<0.001 vs. the Vehicle control, respectively).   
The effect of EphB2 activation on cellular proliferation was also examined. It appeared that 
EphB2 activation increased the proliferation of AGS cells after 48 hours (P= 0.033), but 
decreased the proliferation of HGC27 cells after 24 hours (P= 0.0073) compared to the vehicle 
control (P=0.013 and P=0.000), and no time dependence change was observed (Figure  5C and 
5D). 
Activation of EphB2 promoted the invasion of the GC cells 
As shown in Figure  5E and 5F by an invasion assay, EphB2 activation led to an accelerated 
level of invasion ability of both AGS cells (P=0.00014 vs vehicle) and HGC27 cells (P<0.0001 
vs vehicle). Further, it appeared that the increase of invasion in AGS cells was higher than 
HGC27 cells in response to EphB2 activation (P=0.0085).    
Transcriptional regulatory network of EphB2 in GC 
To establish the Transcriptional regulatory network EphB2 is involved in GC, we preformed 
the gene correlation analysis using the gene profiling data from our cohort. This enabled us to 
identify a panel of the differential genes which correlated with EphB2 either positively or 
negatively (p<0.05) (Figure  6A). To determine the biological pathways and possible cellular 
functions EphB2 is involved in through interacting with the correlated genes in GC, we 
performed a gene ontology (GO) biological process enrichment analysis. As shown in Figure  
6B, EphB2 is mainly involved in cytokine-cytokine receptor interaction, p53 regulation and 
signaling pathway and JAK-STAT signaling pathway. And the affected cellular functions 
include signal transduction, cell communication, response to stimulus and stress, cell death and 
cell adhesion (Figure  6C). The protein interaction network determined by STRING identified 
that EphB2 may interact with the CDH2 signaling linage initially. And CDH2 is associated 
with a panel of GC biomarker proteins such as CDH1, SNAI2, CTGF and TWIST1 (Figure  
6D).      
 
DISCUSSION 
In this study, we evaluated the EphB2 expression in GC tissues using tissue microarray and a 
cohort we obtained. Higher levels of EphB2 expression are observed in GC tumour tissue than 
in adjacent normal or benign gastric tissue specimens, which include the transcript level and 
protein expression. And the transcript level of EphB2 in T3+T4 was significantly higher than 
the group of T1+T2. We therefore demonstrate that EphB2 is overexpressed in GC. Also our 
survival analysis suggests that high gene expression of EphB2 may be associated with poor 
prognosis of patients with GC.  The clinical significance of EphB2 has been investigated in 
some other solid tumour types. The clinical studies in breast and lung cancers seem in line with 
our observation in GC. In breast cancer, 82% (77/94) patients show moderate and strong EphB2 
protein expression, and the increased level of EphB2 expression correlated with poor overall 
survival of patients [21]. And in lung adenocarcinoma, high expression of junctional adhesion 
molecule-A (JAM-A) and EphB2 can together predict the poor overall survival and high 
mortality rate of patients, suggesting its prognostic value [23].  However, EphB2 may play a 
diverse role in colorectal cancer. A study on tissue microarray shows that low EphB2 
expression is linked with more advanced tumour stages, poor differentiation, poor overall 
survival and disease-free survival of patients with colorectal cancer, which may contrast with 
EphB4 [9].  
Additionally, we found a differentiated gene expression of EphB2 in GC between sexes, tissue 
samples from the male exhibited higher expression levels than female samples. 
EphB2 expression appears to be temporally and spatially regulated in the developing mouse 
genital tubercle (GT) and differs between sexes, male pattern of expression can be induced in 
the female GT by dihydrotestosterone exposure. Given dihydrotestosterone exposure 
alters EphB2 expression, this indicates that EphB2 is a candidate androgen regulated gene [24]. 
We show in this study that EphB2 activation significantly decreases the adhesion ability of GC 
cells. By performing correlation gene analysis, we identified several genes which are involved 
in cell adhesion such as ALCAM [25], SIPA1 [26], WISP1 and WISP3.  Meanwhile, EphB2 
activation accelerates both the migration and invasion of gastric cancer cells.  In other cancer 
cell lines, there is evidence that EphB2 regulate migration by modulating the EMT process [27].  
This may also be the case because there is a positive correlation between EphB2 and EMT 
markers including SNAI1 and ECAD.  Also GC cell invasion is promoted by the activation of 
EphB2. It is known that EphB2 has a pro-invasion role in other types of cancer cells [7, 28].  It 
is known that AGS is a poorly differentiated gastric adenocarcinoma cell line, whereas HGC27 
is an undifferentiated GC cell line. Also AGS is a p53 wild-type GC cell line, while HGC27 is 
a p53 mutant cell line [29]. P53 activation transcriptionally regulates the expression of its target 
genes to modulate various cellular processes in response to various tumour-microenvironment 
stress signals, including apoptosis and cell cycle arrest [30]. However, It appears that the role 
of EphB2 is GC cells is less likely p53 dependent. Collectively, as EpB2 play a role in 
decreasing adhesion and accelerate migration and invasion of GC cells, it is likely that EphB2 
may promote metastasis of GC. This can be indirectly supported by studies on some other 
cancer types such as cholangiocarcinoma [31], cutaneous squamous cell carcinoma [32] and 
cervical cancer [27].  
CONCLUSION 
Our research shows that the levels of EphB2 are significantly elevated in tumour tissue 
including gene and protein expression. And the high level of EphB2 expression correlates with 
poor OS. Therefore EphB2 represents as a novel independent prognostic marker in patients 
with GC. The activation of EphB2 in GC cells enhanced the malignant properties of GC cells 
by reducing adhesion but accelerating the migration and invasion abilities. The results therefore 
indicate that EphB2 play a pro-tumour role in GC and present the therapeutic potential for the 
treatment of GC. 
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(Figure and Table description) 
Table 1. Gene expression of EphB2 in the gastric cancer cohort. 
Figure  1. Expression profile of EphB2 protein in a tissue microarray of GC by 
immunohistochemical analysis. (A) Thumbnail image of the tissue microarray after IHC with 
a DHX36 antibody. (B) Protein levels of EphB2 between benign and malignant tissue types. 
(C) Protein levels of EphB2 among GC stages. (D) Protein levels of EphB2 among GC grades. 
(E) Protein levels of EphB2 between sexes. (F) Protein levels of EphB2 among pathological 
subtypes. AD, adenocarcinoma; SC, Stomach carcinoma; SCC, signet ring cell carcinoma; UC, 
undifferentiated carcinoma; MAD, mucinous adenocarcinoma; EJ, esophagogastric junction; 
TAD, Tubular adenocarcinoma.  
Figure  2. Survival analysis of patients with GC based on the mRNA levels of EphB2. (A)  
Overall survival analysis using the qPCR data from our GC cohort. (B-E) Kaplan–Meier 
survival analysis (KMplot, http://kmplot.com) by pooling 876 cases that were subjected to 
expression profiling using Affymetrix gene expression microarray (EphB2 Probe set ID: 
211165_x_at, 209588_at, 210651_s_at and 211165_x_at). Auto-selected cutoff values of 
EphB2 gene expression were applied in the analysis.  
Figure  3. Validation of EphB2 expression after CRISPR-mediated activation in AGS and 
HGC27 cell lines. (A) Flow cytometric analysis of the protein levels of EphB2 in cells.  (B 
and C) Western bolt analysis of the protein levels of EphB2 in cells.  (D) mRNA levels of 
EphB2 in GC cells indicated by qPCR.   
Figure  4. Effect of EphB2 activation on migration of GC cells. (A and B) Migration of the 
GC cell lines indicated by ECIS in AGS and HGC27. * P<0.05 and ** P<0.01 by repeated 
measures ANOVA. (C) Representative images of the wound-healing migration ability of AGS 
cells. (D) Migration ability of AGS cells indicated by the closure of the gap area after scratch 
assay. (E) Representative images of the wound-healing migration ability of HGC27 cells. The 
cell monolayer gaps were highlighted using yellow lines.  (F) Migration ability of HGC27 cells 
indicated by the closure of the gap area after scratch assay. 
Figure  5. Effect of EphB2 activation on adhesion, proliferation and invasion of GC cells. 
(A and B) Adhesion ability of GC cells indicated by crystal violet staining. (C and D) 
Proliferation levels of GC cells indicated by the Alamar Blue Assay. (E) Representative images 
of cell invasion indicated by nuclear staining with Hoechst 33342. (F) Comparison of cell 
invasion by fluorescence plate reading and normalization using the number of seeding cells.     
Figure  6. Analysis of EphB2 correlated genes in GC. (A) Genes which correlate with EphB2 
in the GC cohort (p<0.05 by Pearson test).  (B-D) Significant signaling pathways and cellular 
functions of the EphB2-correlated genes in GC which are determined using the 
ConsensusPathDB-human database system (http://cpdb.molgen.mpg.de/CPDB). (E) The 
interaction network of the EphB2-correlated genes in GC identified using STRING web server 
(http://string-db.org). 
Supplement Figure 1. Representative images showing the different scores of IHC staining 
using a DHX36 antibody. (A)  Staining Intensity. (B) Positive percentage.  
Supplement Figure 2. mRNA expression of EPHB2 in cancer cell lines. (A) mRNA 
expression profile of EPHB2 in cancer cell lines on the website of https://www.proteinatlas.org. 
(B) mRNA expression of EPHB2 in the gastric cancer cell lines in our lab by qPCR assay using 
HUVEC cells as an external positive control. 
Supplement Figure 3. Pooled data analysis of mRNA expression using the publicly 
available Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) data base.  
The database constains 415 GC tumour samples and 35 normal gastric tissue controls. (A) 
mRNA expression of EPHB2 between GC tumou samples and normal tissue controls. (B) 
Comparison among GC stages. (C) Comparison among GC higtological types. (D) 
Comparison among GC grades. (D) Comparison between the female and the male samples. 
The Kruskal-Wallis test was used to evaluate the difference among multiple groups, while the 
Wilcoxon test was used to compare two groups.  The difference was considered statistically 
significant when p<0.05.  
 
 
Table 1. Gene expression of EphB2 in the gastric cancer cohort. 
 
Variable N Mean Median STD SE p-value 
Tumour 171 31785 397 93022 7114   
Normal 97 8267 258 24226 2460 0.0020 
Male 129 38643 961 105509 9290   
Female 42 10718 149 22859 3527 0.0056 
Gastric 132 25419 194 84019 7313   
Cardiac 32 53728 8183 119996 21212 0.2100 
Intestine 2 207 207 269 190 0.0008 
T1 8 21909 773 45418 16058   
T2 10 5319 107 13270 4196 0.3500 
T3 28 32967 1671 128974 24374 0.7100 
T4 120 35470 356 91321 8336 0.4700 
T1+T2 18 12692 309 31852 7508   
T3+T4 148 34996 742 99032 8140 0.0480 
N0 34 35044 491 121607 20855   
N1 22 22270 27 86539 18450 0.6500 
N2 40 36598 249 101016 15972 0.9500 
N3 72 31419 1218 77142 9091 0.8700 
N1+2+3 134 31463 359 85869 7418 0.8700 
TNM1 13 14319 584 36173 10032   
TNM2 26 39416 268 137294 26926 0.3900 
TNM3 122 33653 558 89396 8094 0.1400 
TNM4 4 22555 638 44262 22131 0.7500 
TNM1+2 39 31050 372 113833 18228   
TNM3+4 126 33301 558 88243 7861 0.9100 
Diff-HM 5 58252 6449 121072 54145   
Diff-M 30 48140 481 137422 25090 0.8700 
Diff-ML 40 28756 3446 48435 7658 0.6200 
Diff-L 72 26609 194 95919 11304 0.6000 
Embo-No 76 35744 198 111641 12806   
Embo-Yes 86 30058 1104 78624 8478 0.7100 
Non-Radical 40 14573 67 38708 6120   
Radical 130 37317 946 104021 9123 0.0400 
Alive 68 39752 221 116638 14144   
Died 102 26775 948 73909 7318 0.4200 
Disease-Free 61 40243 224 121097 15505   
Metastasis 7 35473 117 72445 27382 0.8800 
Died of GC 102 26775 948 73909 7318 0.4300 
   
P= 0.019
P=0.012
P=0.0009
P=0.72
P=0.18
P=0.32
n = 18 n = 20 n = 33 n = 23
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